Quantcast

Latest Cambridge Antibody Technology Stories

2008-09-23 03:00:27

OSLO, September 23 /PRNewswire/ -- Affitech AS, the Norwegian human antibody therapeutics company, today announced that it has accomplished the second milestone in its research and licensing collaboration with Roche to produce fully human recombinant antibodies against an unnamed oncology target. Affitech has successfully used its MBAS (Molecule Based Antibody Screening) system that included its proprietary antibody library and high throughput screening technology to identify several fully...

2008-09-17 12:00:35

US-based biopharmaceutical company Regeneron Pharmaceuticals and Columbia University have signed an agreement that will provide researchers at Columbia University Medical Center with access to Regeneron's VelocImmune technology to discover fully human monoclonal antibodies. Under the agreement, scientists at Columbia will use VelocImmune mice to generate antibodies against their research targets and will conduct research to discover potential human therapeutics based on the antibodies....

2008-09-11 15:00:40

GAITHERSBURG, Md. and TOKYO, Sept. 11 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, and SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc., announced today that they have entered into a licensing and collaboration agreement to develop and commercialize SBI Biotech's anti-ILT7 protein for the potential treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. MedImmune has global rights to any resulting product candidates and will be...

2008-09-10 09:00:48

ATHENS, Ga., Sept. 10 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome's ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company. The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of...

2008-09-09 03:00:26

OSLO, Norway, September 9 /PRNewswire/ -- Affitech AS, the Norwegian antibody therapeutics company, today announced that it has appointed Dr Keith McCullagh as non-executive Chairman of its Board of Directors. The Company's previous chairman, Oyvin Broymer, will remain as a member of the Board. Mr Broymer welcomed Dr McCullagh's appointment and said: "I am delighted that Keith McCullagh has agreed to take over from me as Affitech's new chairman. He has an outstanding entrepreneurial track...

2008-09-05 06:00:23

US-based biopharmaceutical company Panacea Pharmaceuticals has received a new US patent that covers antibodies against human aspartyl beta-hydroxylase, a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for the development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence...

2008-09-02 18:00:07

ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone. (Logo:...

2008-08-22 09:00:16

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "There is an urgent medical need for effective treatment options for...

2008-08-14 09:01:14

Morphotek, a subsidiary of Eisai Corporation of North America, has signed a license agreement with the National Cancer Institute for the rights to a monoclonal antibody for a novel antigen identified by the National Cancer Institute researchers. Morphotek said that it will apply its proprietary Morphodoma antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer. This is the second agreement signed in 2008 between the National...

2008-08-13 09:00:13

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the rights to a monoclonal antibody for a novel antigen identified by NCI researchers. Morphotek will apply its proprietary MORPHODOMA(R) antibody technology to the development of novel human therapeutic antibodies for use in the treatment of prostate cancer. "This agreement represents another important milestone in our...